Skip to content
lifestyle.brightsfuture.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Propanc Biopharma, Inc.
CORRECTION — Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
October 22, 2026
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
October 22, 2026
Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer
October 16, 2026
Propanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells
October 16, 2026
Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib
October 7, 2026
Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
September 29, 2026
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
September 22, 2026
Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
September 16, 2026
Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027
September 9, 2026
Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit
August 27, 2026
1
2
3
Next Page
→